BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

311 related articles for article (PubMed ID: 24692813)

  • 1. Effects of replacing metformin with pioglitazone on glycemic control in japanese patients with poorly controlled type 2 diabetes mellitus: A 12-week, open-label, prospective study.
    Sakaue S; Kamigaki M; Yoshimura H; Nishimura M
    Curr Ther Res Clin Exp; 2008 Aug; 69(4):364-77. PubMed ID: 24692813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients.
    Derosa G; Maffioli P; Salvadeo SA; Ferrari I; Ragonesi PD; Querci F; Franzetti IG; Gadaleta G; Ciccarelli L; Piccinni MN; D'Angelo A; Cicero AF
    Metabolism; 2010 Jun; 59(6):887-95. PubMed ID: 20015525
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trial.
    Schernthaner G; Matthews DR; Charbonnel B; Hanefeld M; Brunetti P;
    J Clin Endocrinol Metab; 2004 Dec; 89(12):6068-76. PubMed ID: 15579760
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of simvastatin on the lipid profile and attainment of low-density lipoprotein cholesterol goals when added to thiazolidinedione therapy in patients with type 2 diabetes mellitus: A multicenter, randomized, double-blind, placebo-controlled trial.
    Lewin AJ; Kipnes MS; Meneghini LF; Plotkin DJ; Perevozskaya IT; Shah S; Maccubbin DL; Mitchel YB; Tobert JA;
    Clin Ther; 2004 Mar; 26(3):379-89. PubMed ID: 15110130
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Improved glycemic control and lipid profile in a randomized study of pioglitazone compared with acarbose in patients with type 2 diabetes mellitus.
    Göke B;
    Treat Endocrinol; 2002; 1(5):329-36. PubMed ID: 15832486
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Evaluation of the long-term durability and glycemic control of fasting plasma glucose and glycosylated hemoglobin for pioglitazone in Japanese patients with type 2 diabetes.
    Stringer F; DeJongh J; Enya K; Koumura E; Danhof M; Kaku K
    Diabetes Technol Ther; 2015 Mar; 17(3):215-23. PubMed ID: 25531677
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sibutramine effect on metabolic control of obese patients with type 2 diabetes mellitus treated with pioglitazone.
    Derosa G; D'Angelo A; Salvadeo SA; Ferrari I; Gravina A; Fogari E; Maffioli P; Cicero AF
    Metabolism; 2008 Nov; 57(11):1552-7. PubMed ID: 18940393
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome.
    Kutoh E
    Endocr Res; 2010; 35(3):118-27. PubMed ID: 20712426
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin added to ongoing pioglitazone therapy in patients with type 2 diabetes: a 24-week, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Rosenstock J; Brazg R; Andryuk PJ; Lu K; Stein P;
    Clin Ther; 2006 Oct; 28(10):1556-68. PubMed ID: 17157112
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes.
    Hirose H; Kawai T; Yamamoto Y; Taniyama M; Tomita M; Matsubara K; Okazaki Y; Ishii T; Oguma Y; Takei I; Saruta T
    Metabolism; 2002 Mar; 51(3):314-7. PubMed ID: 11887166
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of Efficacy of Glimepiride, Alogliptin, and Alogliptin-Pioglitazone as the Initial Periods of Therapy in Patients with Poorly Controlled Type 2 Diabetes Mellitus: An Open-Label, Multicenter, Randomized, Controlled Study.
    Kim HJ; Jeong IK; Hur KY; Kim SK; Noh JH; Chun SW; Kang ES; Rhee EJ; Choi SH
    Diabetes Metab J; 2022 Sep; 46(5):689-700. PubMed ID: 35295073
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome.
    Gupta AK; Smith SR; Greenway FL; Bray GA
    Diabetes Obes Metab; 2009 Apr; 11(4):330-7. PubMed ID: 19267711
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes.
    Miyazaki Y; Matsuda M; DeFronzo RA
    Diabetes Care; 2002 Mar; 25(3):517-23. PubMed ID: 11874940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Improvement of glycemic control, triglycerides, and HDL cholesterol levels with muraglitazar, a dual (alpha/gamma) peroxisome proliferator-activated receptor activator, in patients with type 2 diabetes inadequately controlled with metformin monotherapy: A double-blind, randomized, pioglitazone-comparative study.
    Kendall DM; Rubin CJ; Mohideen P; Ledeine JM; Belder R; Gross J; Norwood P; O'Mahony M; Sall K; Sloan G; Roberts A; Fiedorek FT; DeFronzo RA
    Diabetes Care; 2006 May; 29(5):1016-23. PubMed ID: 16644631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of pioglitazone vs glibenclamide on postprandial increases in glucose and triglyceride levels and on oxidative stress in Japanese patients with type 2 diabetes.
    Mori Y; Itoh Y; Obata T; Tajima N
    Endocrine; 2006 Feb; 29(1):143-8. PubMed ID: 16622303
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effect of pioglitazone on serum concentrations of osteoprotegerin in patients with type 2 diabetes mellitus.
    Park JS; Cho MH; Nam JS; Yoo JS; Ahn CW; Cha BS; Kim KR; Lee HC
    Eur J Endocrinol; 2011 Jan; 164(1):69-74. PubMed ID: 20961967
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of pioglitazone/metformin fixed-dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM.
    Perez A; Zhao Z; Jacks R; Spanheimer R
    Curr Med Res Opin; 2009 Dec; 25(12):2915-23. PubMed ID: 19827910
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Glimepiride versus pioglitazone combination therapy in subjects with type 2 diabetes inadequately controlled on metformin monotherapy: results of a randomized clinical trial.
    Umpierrez G; Issa M; Vlajnic A
    Curr Med Res Opin; 2006 Apr; 22(4):751-9. PubMed ID: 16684436
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.